FrancophonIA/ELRC3.0 huggingface dataset:
English: Intrinsa should not be used in naturally menopausal women Efficacy and safety of Intrinsa in naturally menopausal women with HSDD on concomitant estrogen, with or without progestogen, have not been evaluated.
Estonian: Intrinsa efektiivsust ja ohutust loomulikus menopausis HSDD-ga naistel, kes samaaegselt saavad östrogeeni, koos progestageeniga või ilma, ei ole hinnatud.
English: The mode of administration of Intrinsa makes overdose unlikely.
Estonian: Arvestades Intrinsa manustamisviisi, on üleannustamine ebatõenäoline.
English: Intrinsa should not be used in women on concomitant CEE Whereas Intrinsa is indicated with concomitant estrogen therapy, the subgroup of patients receiving oral conjugated equine estrogens (CEE) did not demonstrate a significant improvement in sexual function.
Estonian: Intrinsat ei soovitata kasutada samaaegselt CEE-d võtvatel naistel Et Intrinsa on näidustatud kasutamiseks koos samaaegse östrogeenraviga, ei esinenud suukaudseid konjugeeritud hobuse östrogeene (conjugated equine estrogen, CEE) saavate patsientide alarühmas olulist seksuaalfunktsiooni paranemist.
English: HOW TO USE INTRINSA
Estonian: KUIDAS INTRINSAT KASUTADA
English: Breast pain Breast cyst, clitoral engorgement, enlarged clitoris, genital pruritus, vaginal burning sensation
Estonian: Rinnavalu Rinnanäärmetsüst, kliitori kongestioon, kliitori suurenemine, genitaalide kihelus, põletustunne tupes
English: Intrinsa is designed to systemically deliver 300 micrograms/day.
Estonian: Intrinsa on tehtud nii, et sellest vabaneb ööpäevas süsteemsesse vereringesse 300 mikrogrammi.
English: There were no significant differences in serum estradiol and estrone levels in patients treated with Intrinsa for up to 52 weeks compared to baseline.
Estonian: Patsientidel, keda raviti Intrinsaga kuni 52 nädalat, ei olnud olulisi erinevusi seerumi östradiooli ja östrooni tasemetes võrreldes algtasemega.
English: INFORMATION IN BRAILLE
Estonian: INFORMATSIOON BRAILLE' KIRJAS (PUNKTKIRJAS) Intrinsa
English: The appropriate use and restrictions associated with estrogen therapy should be considered before Intrinsa therapy is initiated and during routine re-evaluation of treatment.
Estonian: Enne Intrinsa-ravi alustamist ja raviefekti igakordsel rutiinsel ümberhindamisel tuleb arvesse võtta östrogeenraviga seotud kohast kasutamist ja piiranguid.
English: - Keep out of the reach and sight of children - Do not use Intrinsa after the expiry date which is stated on the carton and sachet after EXP.
Estonian: - Ärge kasutage Intrinsat pärast kõlblikkusaega, mis on märgitud karbil ja kotikesel pärast märget
English: HOW TO STORE INTRINSA
Estonian: KUIDAS INTRINSAT SÄILITADA
English: Marketing Authorisation Holder Warner Chilcott UK Limited Old Belfast Road Millbrook, Larne
Estonian: Müügiloa hoidja Warner Chilcott UK Limited Old Belfast Road Millbrook, Larne County Antrim BT40 2SH
English: What Intrinsa looks like and contents of the pack Intrinsa is a thin, clear, oval patch with T001 stamped on the back.
Estonian: Intrinsa on õhuke sile ovaalne plaaster, mille pealiskihile on trükitud T001.
English: Intrinsa 300 micrograms/24 hours transdermal patch Testosterone
Estonian: Intrinsa transdermaalne plaaster 300 mikrogrammi 24 tunni jooksul Testosteroon
English: BEFORE YOU USE INTRINSA
Estonian: MIDA ON VAJA TEADA ENNE INTRINSA KASUTAMIST
English: Breastfeeding Intrinsa must not be used by breast-feeding women.
Estonian: Imetamine Imetavad naised ei tohi Intrinsat kasutada.
English: Paediatric population There is no relevant use of Intrinsa in the paediatric population.
Estonian: Lapsed Puudub Intrinsa asjakohane kasutamine lastel.
English: However, this is not expected from the low dose of testosterone delivered by the Intrinsa patch.
Estonian: Intrinsa plaastrist vabanevad väikesed testosterooni annused seda siiski ei põhjusta.
English: NAME OF THE MEDICINAL PRODUCT Intrinsa 300 micrograms/24 hours transdermal patch
Estonian: RAVIMPREPARAADI NIMETUS Intrinsa transdermaalne plaaster 300 mikrogrammi 24 tunni jooksul
English: BT40 2SH
Estonian: SHBG (nmol/l)
English: NAME OF THE MEDICINAL PRODUCT Intrinsa 300 micrograms/24 hours transdermal patch Testosterone
Estonian: RAVIMPREPARAADI NIMETUS Intrinsa transdermaalne plaaster 300 mikrogrammi 24 tunni jooksul Testosteroon
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Intrinsa 300 micrograms/24 hours transdermal patch Testosterone
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE Intrinsa transdermaalne plaaster 300 mikrogrammi 24 tunni jooksul Testosteroon
English: Intrinsa is not recommended in naturally
Estonian: Loomulikus menopausis naistel Intrinsat kasutada ei soovitata.
English: Oral use blister OPA/alu/PVC/alu 7 tablets
Estonian: Suukaudne blister OPA/alu/PVC/alu)
English: Strength Pharmaceutical Form
Estonian: Ravimvorm Manustamiste e
English: Lutathera lutetium (
Estonian: Lutathera luteetsium-(
English: Lu) oxodotreotide
Estonian: Lu)-oksodotreotiid
English: What measures are being taken to ensure the safe and effective use of Lutathera?
Estonian: Mis meetmed võetakse, et tagada Lutathera ohutu ja efektiivne kasutamine?
English: Lutathera must not be given to women who are pregnant or in whom pregnancy has not been excluded.
Estonian: Lutatherat ei tohi kasutada raseduse ajal ega juhul, kui rasedus ei ole välistatud.
English: The patient cannot leave the controlled areas until told to do so by the doctor.
Estonian: Patsient ei tohi eriruumidest lahkuda, enne kui seda lubab arst.
English: It is a radiopharmaceutical (a medicine that emits a small amount of radioactivity).
Estonian: See on radiofarmatseutikum (ravim, mis eraldab väikeses koguses radioaktiivset kiirgust).
English: What is Lutathera and what is it used for?
Estonian: Mis on Lutathera ja milleks seda kasutatakse?
English: The usual treatment involves 4 infusions 8 weeks apart, but the gap between infusions can be increased to up to 16 weeks if the patient gets severe side effects.
Estonian: Tavaliselt koosneb ravi 4 infusioonist iga 8 nädalatagant, kuid infusioonide vaheaega võib pikendada 16 nädalani, kui patsiendil tekivad rasked kõrvalnähud.
English: The most common side effects seen with Lutathera treatment are nausea and vomiting, which occurred at the start of the infusions in around half of patients and may be related to the amino acid infusion.
Estonian: Lutathera kõige sagedamad kõrvalnähud on iiveldus ja oksendamine, mis esinesid infusioonide alguses ligikaudu pooltel patsientidel ja mis võivad olla seotud aminohapete infusiooniga.
English: Other information about Lutathera
Estonian: Muu teave Lutathera kohta
English: It is not intended to provide practical advice on how to use Lutathera.
Estonian: Hindamisaruandes ei anta Lutathera kasutamise praktilisi nõuandeid.
English: The European Medicines Agency considered that the benefits seen with Lutathera outweigh its risks and recommended it be approved in the EU.
Estonian: Euroopa Ravimiamet järeldas, et Lutathera kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lutathera have also been included in the summary of product characteristics and the package leaflet.
Estonian: Lutathera ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: What are the risks associated with Lutathera?
Estonian: Mis riskid Lutatheraga kaasnevad?
English: Lutathera is used is to treat GEP-NETs that cannot be removed by surgery, have spread to other parts of the body or are not responding to treatment.
Estonian: Lutatherat kasutatakse selliste GEP-NET-kasvajate raviks, mida ei saa eemaldada kirurgiliselt, mis on levinud organismis ka mujale või mis ei reageeri ravile.
English: Other common side effects affecting more than 1 in 10 patients are thrombocytopenia (low platelet counts), lymphopenia (low levels of lymphocytes, a type of white blood cell), anaemia (low red cell counts), pancytopenia (low levels of all types of blood cells), tiredness and reduced appetite.
Estonian: Muud sagedad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on trombotsütopeenia (trombotsüütide ehk vereliistakute vähesus), lümfopeenia (lümfotsüütide ehk teatud valgeliblede vähesus), aneemia (erütrotsüütide ehk vere punaliblede vähesus), pantsütopeenia (igat tüüpi vererakkude vähesus), väsimus ja isutus.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Lutathera can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Lutathera kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Why is Lutathera approved?
Estonian: Miks Lutathera heaks kiideti?
English: The full EPAR for Lutathera can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Lutathera kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It must also not be given to patients with severely reduced kidney function.
Estonian: Seda ei tohi kasutada ka neeru raske talitlushäirega patsiendid.
English: Lutathera can help slow the worsening of the condition and its side effects are considered manageable.
Estonian: Lutathera võib aidata aeglustada kasvajate progresseerumist ning selle kõrvalnähte peetakse hallatavateks.
English: Before starting treatment, the doctor will have checked that the patient's tumours have somatostatin receptors on their cell surfaces.
Estonian: Enne ravi alustamist peab arst kontrollima, kas patsiendi kasvajarakkude pinnal on somatostatiini retseptorid.
English: The company that markets Lutathera will put in place an educational programme for patients to ensure they understand the risk of radioactivity and precautions they should take to limit exposure to themselves and people around them.
Estonian: Lutathera turustaja koostab teabematerjali patsientidele, kus selgitab radioaktiivsuse riski ja vajalikke ettevaatusmeetmeid, et piirata enda ja teiste inimeste kokkupuudet radioaktiivse kiirgusega.
English: The radioactivity it emits then kills the tumour cells it is attached to but has little effect on neighbouring cells.
Estonian: Toimeainest eralduv radioaktiivne kiirgus hävitab seejärel kasvajarakud, millega toimeaine on seondunud, kahjustamata seejuures oluliselt naaberrakke.
English: Because Lutathera emits some radioactivity, it is only used in special controlled areas and must be handled and given to patients by qualified personnel.
Estonian: Et Lutathera eraldab teatavas koguses radioaktiivset kiirgust, kasutatakse seda üksnes eriruumides ning seda peavad käsitsema ja patsientidele manustama asjakohase väljaõppega meditsiinitöötajad.
English: Lutathera contains the active substance lutetium (177Lu) oxodotreotide.
Estonian: Lutathera sisaldab toimeainena luteetsium-(177Lu)-oksodotreotiidi.
English: Lutathera is a cancer medicine for treating tumours in the gut known as gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Estonian: Lutathera on vähiravim, mida kasutatakse soolestiku gastroenteropankreaatiliste neuroendokriinsete kasvajate (GEP-NET) raviks.
English: In a main study of 229 patients with GEP-NETs that contained somatostatin receptors, patients given Lutathera lived for an average of 28 months without their disease getting worse.
Estonian: Ühes põhiuuringus (229 patsienti, kelle GEP-NET-kasvajal olid somatostatiini retseptorid) oli Lutatherat kasutanud patsientide keskmine progresseerumiseta elumus 28 kuud ja oktreotiidi (seisundi raviks juba heaks kiidetud teine ravim) kasutanud patsientidel 9 kuud.
English: How does Lutathera work?
Estonian: Kuidas Lutathera toimib?
English: Only a minority of patients with GEP-NETs can be cured with surgery and at the time of diagnosis the tumours would have spread in most patients.
Estonian: Üksnes vähestel GEP-NET-kasvajatega patsientidel saab kasvaja eemaldada kirurgiliselt ning enamikul patsientidel on kasvajad diagnoosimise ajaks juba levinud organismis ka mujale.
English: Because the number of patients with GEP-NETs is low, they are considered ‘rare', and Lutathera was designated an ‘orphan medicine' (a medicine used in rare diseases) on 31 January 2008.
Estonian: Et GEP-NET-kasvajatega patsientide arv on väike ja see haigus esineb harva, nimetati Lutathera 31. jaanuaril 2008 harvikravimiks.
English: Lutathera can help slow down the worsening of GEP-NETs.
Estonian: Lutathera võib aidata aeglustada GEP-NET-kasvajate progresseerumist (süvenemist).
English: For practical information about using Lutathera, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Lutathera kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Lutathera, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Lutatheraga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The active substance in Lutathera, lutetium (177Lu) oxodotreotide, works by attaching to somatostatin receptors, which are found in high numbers in some GEP-NETs.
Estonian: Lutathera toimeaine luteetsium-(177Lu)-oksodotreotiid seondub somatostatiini retseptoritega, mida leidub teatud GEP-NET-kasvajates rohkesti.
English: How is Lutathera used?
Estonian: Kuidas Lutatherat kasutatakse?
English: For the full list of all side effects reported with Lutathera, see the package leaflet.
Estonian: Lutathera kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What benefits of Lutathera have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Lutathera kasulikkus?
English: This is a summary of the European public assessment report (EPAR) for Lutathera.
Estonian: See on ravimi Lutathera Euroopa avaliku hindamisaruande kokkuvõte.
English: The patient should also be given an infusion of an amino acid solution which helps protect their kidneys.
Estonian: Neerude kaitsmiseks tuleb patsiendile infusiooniga manustada ka aminohappelahust.
English: For further information, including information on the precise method for giving the infusions, see the package leaflet.
Estonian: Lisateave koos üksikasjalike infusioonijuhistega on pakendi infolehel.
English: The medicine is only for GEP-NETs that have receptors called somatostatin receptors on their cell surfaces.
Estonian: Ravim on näidustatud üksnes juhul, kui GEP-NET-kasvajate rakkude pinnal on somatostatiini retseptorid.
English: Lutathera is given by infusion (drip) into a vein.
Estonian: Lutatherat manustatakse veeniinfusioonina.
English: They are taken once a day.
Estonian: Seda manustatakse üks kord ööpäevas.
English: 20 December 2010
Estonian: 20. detsember 2010
English: The European Commission issued a decision on this opinion on 20 December 2010.
Estonian: Euroopa Komisjon tegi otsuse selle arvamuse kohta 20. detsembril 2010.
English: Why was Ethirfin reviewed?
Estonian: Miks Ethirfin uuesti üle vaadati?
English: It is used to treat severe pain.
Estonian: Seda kasutatakse tugeva valu raviks.
English: This renewal was to be recognised in Germany, Ireland, Italy and the United Kingdom (the ‘concerned Member States').
Estonian: Pikendamist pidid tunnustama ka Saksamaa, Iirimaa, Itaalia ja Ühendkuningriik (asjaomased liikmesriigid).
English: What is Ethirfin?
Estonian: Mis on Ethirfin?
English: Ethirfin was authorised in the European Union (EU) under a mutual recognition procedure on the basis of the initial authorisation granted by Denmark on 15 July 2005.
Estonian: Ethirfinil on müügiluba Euroopa Liidus vastastikuse tunnustamise menetluse alusel vastavalt Taanis 15. juulil 2005 välja antud esialgsele müügiloale.
English: Therefore the benefits of Ethirfin do not outweigh its risks, and the marketing authorisation for Ethirfin should not be renewed in all concerned Member States.
Estonian: Seetõttu ei ole Ethirfini kasulikkus suurem kui sellega kaasnevad riskid ning asjassepuutuvates liikmesriikides ei tohi Ethirfini müügiluba pikendada.
English: Ethirfin is a medicine that contains the active substance morphine sulphate.
Estonian: Ethirfin on ravim, mis sisaldab toimeainena morfiinsulfaati.
English: The European Medicines Agency has completed an arbitration procedure for Ethirfin and associated names.
Estonian: Euroopa Ravimiamet on lõpetanud Ethirfini ja sarnaste nimetuste vahekohtumenetluse.
English: Because these Member States were not able to reach an agreement, the German and United Kingdom medicines regulatory agencies referred the matter to the CHMP for arbitration on 30 October 2009.
Estonian: Liikmesriigid ei jõudnud küsimuses üksmeelele ja Saksamaa ja Ühendkuningriigi pädevad asutused tegid 30. oktoobril 2009 inimravimite komiteele esildise vahekohtumenetluse alustamiseks.
English: The company applied for the marketing authorisation to be renewed in Denmark (the ‘reference Member State').
Estonian: Ettevõte esitas Taanis (viiteliikmesriigis) müügiloa pikendamise taotluse.
English: Questions and answers on Ethirfin and associated names (morphine sulphate, prolonged-release capsules, 20, 60, 120 and 200 mg)
Estonian: Teave Ethirfini ja sarnaste nimetuste kohta (morfiinsulfaat, pikendatud vabanemisajaga kapslid, 20, 60, 120 ja 200 mg)
English: Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that there is a significant interaction between Ethirfin and alcohol, and that patients taking Ethirfin and alcohol are at risk of developing serious side effects.
Estonian: Praegu olemasolevate andmete hindamise ja komiteesisese teadusliku arutelu alusel järeldas inimravimite komitee, et ravimi Ethirfin ja alkoholi vahel on oluline koostoime ning et Ethirfini ja alkoholi koos manustavatel patsientidel esineb risk raskete kõrvaltoimete tekkeks.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) had been asked to arbitrate on the renewal of the marketing authorisation for Ethirfin.
Estonian: Ravimiameti inimravimite komiteed on palutud vahekohtunikuks Ethirfini müügiloa pikendamisel.
English: The rapid release of the active substance is called ‘dose dumping' and could put patients at risk of exposure to large doses of morphine, leading to side effects such as respiratory depression (an inhibition of breathing).
Estonian: Toimeaine kiiret vabanemist nimetatakse äkilise vabanemise efektiks ning see võib patsientidel tekitada riski suurte morfiiniannustega kokkupuuteks, mis põhjustab selliseid kõrvalnähtusid nagu respiratoorne depressioon (hingamispeetus).
English: Questions and answers on Ethirfin and associated names (morphine sulphate, prolonged-release capsules, 20, 60, 120 and 200 mg) EMA/297829/2011
Estonian: Teave Ethirfini ja sarnaste nimetuste kohta (morfiinsulfaat, pikendatud vabanemisajaga kapslid, 20, 60, 120 ja 200 mg) EMA/276994/2011
English: Ethirfin is available as ‘prolonged-release' capsules that release the active substance slowly.
Estonian: Ethirfini turustatakse pikendatud vabanemisega kapslitena, mis vabastavad toimeainet aeglaselt.
English: The Committee concluded that the marketing authorisation should not be renewed, as patients taking Ethirfin and alcohol are at risk of developing serious side effects.
Estonian: Komitee järeldas, et müügiluba ei tohi pikendada, sest Ethirfini ja alkoholi koos tarvitavatel patsientidel esineb raskete kõrvalnähtude risk.
English: The grounds for the referral were concerns that the active substance in the capsules could be released too quickly if the capsules are taken with alcohol, because they contain a ‘polymethacrylatetriethylcitrate' coating to control the release of morphine and this coating is soluble in alcohol.
Estonian: Esildise aluseks olid kahtlused, et kapslites olev toimeaine vabaneb liiga kiiresti, kui kapslitega koos manustatakse alkoholi, sest antud kapslid on kaetud polümetakrülaat-trietüültsitraadiga, mis juhib morfiini vabanemist; selline kate on alkoholis lahustuv.
English: Strength Pharmaceutical form
Estonian: Nimetus Tugevus Ravimvorm Loomalii gid
English: Packaging Content
Estonian: Manustamisviis Pakend Sisaldus
English: Annex IV Scientific conclusions and grounds for maintenance of the marketing authorisations or the variation to the terms of the marketing authorisations, as relevant
Estonian: IV lisa Teaduslikud järeldused ja müügilubade säilitamise või müügilubade tingimuste muutmise alused, vastavalt vajadusele
English: More than half of these patients had taken HIV treatment in the past.
Estonian: Enam kui pooled neist olid varem kasutanud HIV-ravimeid.
English: This finding was maintained after 96 weeks.
Estonian: Sama leid püsis ka 96 nädala järel.
English: What measures are being taken to ensure the safe and effective use of Reyataz?
Estonian: Mis meetmed võetakse, et tagada Reyatazi ohutu ja efektiivne kasutamine?
English: The full EPAR for Reyataz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Reyatazi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Reyataz on 2 March 2004.
Estonian: Euroopa Komisjon andis Reyatazi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 2. märtsil
English: In patients who had been treated before, the results of the first study could not be interpreted, as a large number of patients left the study before its planned end.
Estonian: Varem ravitud patsientidel ei saanud esimese uuringu tulemusi hinnata, sest suur osa patsiente lahkus uuringust enne selle kavandatud lõppu.
English: It is available as capsules (100 mg, 150 mg, 200 mg and 300 mg) and oral powder (50 mg).
Estonian: Seda turustatakse kapslitena (100 mg, 150 mg, 200 mg ja 300 mg) ja suukaudse pulbrina (50 mg).
English: Reyataz atazanavir
Estonian: Reyataz atasanaviir
English: The patients also had improvements in their immune systems.
Estonian: Patsientidel paranes ka immuunsüsteemi talitlus.
English: In studies, side effects were similar in younger patients.
Estonian: Noorte patsientide kõrvalnähud olid uuringutes sarnased.
English: For adults (aged 18 years or over), the recommended dose is 300 mg once a day.
Estonian: Täiskasvanute (vähemalt 18-aastased) soovitatav annus on 300 mg üks kord ööpäevas.
English: Reyataz does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: Reyataz ei ravi HIV-nakkust ega AIDS-i välja, kuid võib immuunsüsteemi kahjustumise ja AIDS-iga kaasnevate infektsioonide ja haiguste tekke edasi lükata.
English: The Committee decided that Reyataz's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Reyatazi kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: The main measure of effectiveness was the change in the levels of HIV in the patients' blood (viral load).
Estonian: Efektiivsuse põhinäitaja oli patsientide vere HIV-sisalduse (viiruskoormuse) muutus.
English: Treatment with Reyataz should be started by a doctor who has experience in the treatment of HIV infection.
Estonian: Ravi Reyataziga peab alustama HIV-nakkuse ravis kogenud arst.
English: In all of the studies, the patients also took two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs, a type of antiviral medicine).
Estonian: Kõigis uuringutes kasutasid patsiendid ka kahte nukleosiidset või nukleotiidset pöördtranskriptaasi inhibiitorit (NRTI, samuti viiruseravim).